Cost-effectiveness and budget impact of Empirical vitamin D therapy on unintentional falls in older adults in the UK

Poole, Christopher David; Smith, Jessi L.; Davies, John Stephen

doi:10.1136/bmjopen-2015-007910

Cited by 29 publications

(27 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Economic evaluations of a variety of other falls prevention programs (vitamin D, cataract surgery, cardiac pacing, podiatry care, bisphosphonates and exercise, cognitive behavioral therapy) were reported in 13 studies . Eleven ICERs of CUAs were reported in these studies, of which 7 programs were cost saving or cost‐effective . Nine were cost‐effective given a threshold of $100,000 per QALY.…”

Section: Resultsmentioning

confidence: 99%

Economic Evaluations of Falls Prevention Programs for Older Adults: A Systematic Review

Olij

Ophuis

Polinder

et al. 2018

J American Geriatrics Society

View full text Add to dashboard Cite

OBJECTIVES: To provide a comprehensive overview of economic evaluations of falls prevention programs and to evaluate the methodology and quality of these studies. DESIGN: Systematic review of economic evaluations on falls prevention programs. SETTING: Studies (N=31) of community-dwelling older adults (n=25), of older adults living in residential care facilities (n=3), and of both populations (n=3) published before , medication adjustment (n = 4), multifactorial programs (n = 11), and various other programs (n = 13) were identified. Approximately twothirds of all reported incremental cost-effectiveness ratios (ICERs) with quality-adjusted life-years (QALYs) as outcome were below the willingness-to-pay threshold of $50,000 per QALY. All studies on home assessment and medication adjustment programs reported favorable ICERs, whereas the results of studies on exercise and multifactorial programs were inconsistent. The overall methodological quality of the studies was good, although there was variation between studies. CONCLUSION: The majority of the reported ICERs indicated that falls prevention programs were cost-effective, but methodological differences between studies hampered direct comparison of the cost-effectiveness of program types. The results imply that investing in falls prevention programs for adults aged 60 and older is cost-effective. Home assessment programs (ICERs < $40,000/QALY) were the most costeffective type of program for community-dwelling older adults, and medication adjustment programs (ICERs < $13,000/ QALY) were the most cost-effective type of program for older adults living in a residential care facility.

show abstract

Section: Resultsmentioning

confidence: 99%

Economic Evaluations of Falls Prevention Programs for Older Adults: A Systematic Review

Olij

Ophuis

Polinder

et al. 2018

J American Geriatrics Society

View full text Add to dashboard Cite

show abstract

“…The identified studies spanned a period of 20 years, with the earliest being published in 1995 and the majority emerging between 2012 and 2016. Studies were carried out in the UK (15)(16)(17)(18)(19), the USA (20,21), Australia (22,23), France (24), Finland (25), Sweden (26) and Germany (27). Additionally, there was one multi-country study that carried out cost-effectiveness analyses in seven European countries (28).…”

Section: General Characteristics Of the Included Studiesmentioning

confidence: 99%

“…Additionally, there was one multi-country study that carried out cost-effectiveness analyses in seven European countries (28). The majority of studies (n=7) evaluated supplementation strategies of vitamin D alone in the adult population (16,17,20,21,(23)(24)(25). Other studies investigated calcium and vitamin D interventions either through oral supplements (n=4) (15,22,26,28) or food fortification (n=1) (27).…”

Section: General Characteristics Of the Included Studiesmentioning

confidence: 99%

“…Eight studies evaluated interventions using supplements with vitamin D alone (16-18, 20-22, 24, 25) ( Table 1) and all except one (18) focused on the elderly population. Five were cost-utility analyses using quality-adjusted life-years (QALYs) to measure benefits (16,20,21,23,24), two were costeffectiveness analyses (17,25) and one was a cost-consequence analysis (18). Three studies compared universal supplementation against screening for VDD followed by supplementation (18,21,24), three studies evaluated vitamin supplements against interventions to prevent falls (20,23,25) and two evaluated supplements against current care to prevent fractures (17) and falls (16) .…”

Section: Supplementation With Vitamin D Alonementioning

confidence: 99%

See 1 more Smart Citation

Preventing vitamin D deficiency (VDD): a systematic review of economic evaluations

Aguiar

Andronis

Pallan

et al. 2017

European Journal of Public Health

View full text Add to dashboard Cite

show abstract

“…A concept of pharmacoeconomics has been applied to a clinical pharmacy practice, 3,4) and a health care evaluation.…”

mentioning

confidence: 99%

Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer

Chisaki

Nakamura

Yano

2017

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

The purpose of this study was to propose a time-series modeling and simulation (M&S) strategy for probabilistic cost-effective analysis in cancer chemotherapy using a Monte-Carlo method based on data available from the literature. The simulation included the cost for chemotherapy, for pharmaceutical care for adverse events (AEs) and other medical costs. As an application example, we describe the analysis for the comparison of four regimens, cisplatin plus irinotecan, carboplatin plus paclitaxel, cisplatin plus gemcitabine (GP), and cisplatin plus vinorelbine, for advanced non-small cell lung cancer. The factors, drug efficacy explained by overall survival or time to treatment failure, frequency and severity of AEs, utility value of AEs to determine QOL, the drugs' and other medical costs in Japan, were included in the model. The simulation was performed and quality adjusted life years (QALY) and incremental cost-effectiveness ratios (ICER) were calculated. An index, percentage of superiority (%SUP) which is the rate of the increased cost vs. QALYgained plots within the area of positive QALY-gained and also below some threshold values of the ICER, was calculated as functions of threshold values of the ICER. An M&S process was developed, and for the simulation example, the GP regimen was the most cost-effective, in case of threshold values of the ICER $70000/ year, the %SUP for the GP are more than 50%. We developed an M&S process for probabilistic cost-effective analysis, this method would be useful for decision-making in choosing a cancer chemotherapy regimen in terms of pharmacoeconomic.Key words pharmacoeconomic; cost-effectiveness; cancer chemotherapy; Monte Carlo simulation; modeling and simulation; non-small cell lung cancer In cancer chemotherapy, an important concern for patients is the efficacy of treatment, usually expressed by indices such as survival time and performance status. The high cost of cancer chemotherapy is a burden for both patients and the national economy; for example, the total cost of cancer therapy in the United States reported by National Cancer Institute (NCI) was $157 billion in 2010.1) It has also been reported that these costs may increase at a faster rate than overall medical expenditure 2) because new targeted anticancer therapies such as monoclonal antibodies and small-molecule inhibitors will be adopted as standard therapies, and therefore, more efficient but more expensive therapies will be used.A concept of pharmacoeconomics has been applied to a clinical pharmacy practice, 3,4) and a health care evaluation. 5)Several types of cost-effective analyses have been performed for choosing the optimal chemotherapy regimens for cancer patients. [6][7][8] The objectives of these cost-effective analyses were to compare two or more regimens from the viewpoint of increasing cost per increasing efficacy. From a pharmaceutical viewpoint, in order to choose the optimal regimen that provides the best cost-effective ratio, information regarding both treatments' efficacy and the frequency an...

show abstract

Cost-effectiveness and budget impact of Empirical vitamin D therapy on unintentional falls in older adults in the UK

Cited by 29 publications

References 36 publications

Economic Evaluations of Falls Prevention Programs for Older Adults: A Systematic Review

Economic Evaluations of Falls Prevention Programs for Older Adults: A Systematic Review

Preventing vitamin D deficiency (VDD): a systematic review of economic evaluations

Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer

Contact Info

Product

Resources

About